CA2432883A1 - Antigenic ck-18 compounds for therapy and diagnosis and methods for using same - Google Patents

Antigenic ck-18 compounds for therapy and diagnosis and methods for using same Download PDF

Info

Publication number
CA2432883A1
CA2432883A1 CA002432883A CA2432883A CA2432883A1 CA 2432883 A1 CA2432883 A1 CA 2432883A1 CA 002432883 A CA002432883 A CA 002432883A CA 2432883 A CA2432883 A CA 2432883A CA 2432883 A1 CA2432883 A1 CA 2432883A1
Authority
CA
Canada
Prior art keywords
seq
protein
peptide
agent
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002432883A
Other languages
English (en)
French (fr)
Inventor
Charles A. Nicolette
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2432883A1 publication Critical patent/CA2432883A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4741—Keratin; Cytokeratin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4742—Keratin; Cytokeratin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA002432883A 2000-12-21 2001-12-21 Antigenic ck-18 compounds for therapy and diagnosis and methods for using same Abandoned CA2432883A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25782000P 2000-12-21 2000-12-21
US60/257,820 2000-12-21
PCT/US2001/049964 WO2002055555A2 (en) 2000-12-21 2001-12-21 Antigenic ck-18 compounds for therapy and diagnosis and methods for using same

Publications (1)

Publication Number Publication Date
CA2432883A1 true CA2432883A1 (en) 2002-07-18

Family

ID=22977885

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002432883A Abandoned CA2432883A1 (en) 2000-12-21 2001-12-21 Antigenic ck-18 compounds for therapy and diagnosis and methods for using same

Country Status (5)

Country Link
US (1) US20020122791A1 (enExample)
EP (1) EP1345961A2 (enExample)
JP (1) JP2005500812A (enExample)
CA (1) CA2432883A1 (enExample)
WO (1) WO2002055555A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8980568B2 (en) 2001-10-11 2015-03-17 Aviva Biosciences Corporation Methods and compositions for detecting non-hematopoietic cells from a blood sample
US8986944B2 (en) 2001-10-11 2015-03-24 Aviva Biosciences Corporation Methods and compositions for separating rare cells from fluid samples
WO2005074968A2 (en) * 2004-02-10 2005-08-18 Universiteit Maastricht Medical use of basic peptides
KR100756972B1 (ko) * 2005-02-05 2007-09-07 전숙영 만성폐쇄성폐질환의 예방, 치료 및 진단용 조성물 및 방법
CA2657621A1 (en) 2006-07-14 2008-01-17 Aviva Biosciences Corporation Methods and compositions for detecting rare cells from a biological sample

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4754065A (en) * 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5837249A (en) * 1985-04-19 1998-11-17 The Wistar Institute Method for generating an immunogenic T cell response protective against a virus
US4800159A (en) * 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
SE470273B (sv) * 1990-09-24 1993-12-20 Idl Immunodeveloplab Ab Cytokeratinfragment, deras framställning och användning, framställning av monoklonala antikroppar och testkit för epitelialcancer
EP0573608A1 (en) * 1991-02-07 1993-12-15 Molecumetics, Ltd. Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
SE9500023L (sv) * 1994-05-17 1995-11-18 Beki Ab Sätt att detektera cancer
DE19716346C1 (de) * 1997-04-18 1998-11-19 Christoph Prof Dr Wagener Verfahren zum Nachweis von Cytokeratinen

Also Published As

Publication number Publication date
US20020122791A1 (en) 2002-09-05
WO2002055555A2 (en) 2002-07-18
EP1345961A2 (en) 2003-09-24
JP2005500812A (ja) 2005-01-13
WO2002055555A3 (en) 2003-02-27

Similar Documents

Publication Publication Date Title
US7326529B2 (en) Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
ES2317704T3 (es) Un nuevo metodo para el diagnostico, seguimiento, estadificacion. imagineria y tratamiento de distintos canceres.
US6730477B1 (en) Method of diagnosing, monitoring and staging breast cancer
CA2400703A1 (en) Compositions and methods for the early diagnosis of ovarian cancer
CA2402017A1 (en) Compositions and methods for the early diagnosis of ovarian cancer
Kariyama et al. Expression of MAGE-1 and-3 genes and gene products in human hepatocellular carcinoma
JP2003526342A (ja) 乳癌の診断、モニタニング、ステージング、イメージングおよび処置の新規方法
WO2000020640A1 (en) A novel method of diagnosing, monitoring, staging, imaging and treating gastrointestinal cancers
US6858386B1 (en) Method of diagnosing, monitoring, staging, imaging and treating colon cancer
Scholl et al. Is primary chemotherapy useful for all patients with primary invasive breast cancer?
US6902890B1 (en) Method of diagnosing monitoring, staging, imaging and treating cancer
JP3524536B2 (ja) 癌の診断、モニタリング、ステージング、イメージングおよび処置のための新規方法
JP3524537B2 (ja) 癌の診断、モニタリング、ステージング、イメージングおよび処置のための新規方法
US20080107596A1 (en) Novel Method of Diagnosing, Monitoring, Staging, Imaging and Treating Breast Cancer
WO2002006515A2 (en) Method of diagnosing, monitoring, staging, imaging and treating colon cancer
EP1169066A1 (en) A novel method of diagnosing, monitoring, staging, imaging and treating gynecologic cancers
EP1365242A1 (en) Compounds for detection and treatment of colorectal lesions
CA2346326A1 (en) A novel method of diagnosing, monitoring, staging and treating gynecological and prostatic cancers
Morales et al. Does eradication of H. pylori reverse gastric intestinal metaplasia? Long-term follow-up utilizing methylene blue staining
Moon et al. The relationship between dysplasia and mutations of p53: A Ki-ras gene in ulcerative colitis
Monges et al. Thymidylate synthase (TS) and P53 expression predict event-free survival (EFS) but not the response to adjuvant chemotherapy of patients with colonic carcinoma (CC)
CA2387864A1 (en) Nuclear matrix proteins, polynucleotide sequences encoding them, and their use
WO2004040298A2 (en) Tumor marker proteins for diagnosis and therapy of cancer and cancer risk assessment

Legal Events

Date Code Title Description
FZDE Discontinued